{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-23-000059","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.062971+00:00","generated_at":"2026-06-13T08:32:29.335840+00:00","sec_items":["3.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aspira Women's Health receives Nasdaq delisting notice for MVLS below $35M","bullets":["Nasdaq notified Aspira on July 11, 2023 that its Market Value of Listed Securities was below $35M for 30 consecutive business days.","Company has 180-day grace period, until January 8, 2024, to regain compliance with the MVLS requirement.","To regain compliance, MVLS must be $35M+ for 10 consecutive business days; alternative is equity above $2.5M.","If not compliant by deadline, Nasdaq may delist stock; Aspira may appeal any delisting determination."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-23-000059","json":"https://secwatch.observer/filing/0000926617-23-000059.json","markdown":"https://secwatch.observer/filing/0000926617-23-000059.md","text":"https://secwatch.observer/filing/0000926617-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000059/0000926617-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000059/awh-20230711x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:32:29.335840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfd86f3c4ee51befeac7cb39016d3723a220e944","claim":"Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).","evidence_excerpt":"July 11, 2023, Aspira Women’s Health Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the Company’s minimum Market Value of Listed Securities was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Compan","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000059/0000926617-23-000059-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2), 5810(c)(3)(C)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}